Chikungunya vaccines in development

References

• Weaver SC, Lecuit M. Chikungunya virus and the global spread of a mosquito-borne disease. N Engl J Med 2015; 372:1231-9; PMID:25806915; http://dx.doi.org/10.1056/NEJMra1406035
   PubMed Web of Science ®Google Scholar
• Robinson MC. An epidemic of virus disease in Southern Province, Tanganyika Territory, in 1952-53. I. Clinical features. Trans R Soc Trop Med Hyg 1955; 49:28-32; PMID:14373834; http://dx.doi.org/10.1016/0035-9203(55)90080-8
   PubMedGoogle Scholar
• Rezza G. Dengue and chikungunya: long-distance spread and outbreaks in naive areas. Pathog Glob Health 2014; 108:349-55; PMID:25491436; http://dx.doi.org/10.1179/2047773214Y.0000000163
   PubMed Web of Science ®Google Scholar
• WHO. Chikungunya Fact sheet N°327. 2015; http://www.who.int/mediacentre/factsheets/fs327/en/ (accessed June 18th, 2015).
   Google Scholar
• Ross RW. The Newala epidemic. III. The virus: isolation, pathogenic properties and relationship to the epidemic. J Hyg 1956; 54:177-91; PMID:13346078; http://dx.doi.org/10.1017/S0022172400044442
   PubMedGoogle Scholar
• Moyen N, Thiberville SD, Pastorino B, Nougairede A, Thirion L, Mombouli JV, Dimi Y, Leparc-Goffart I, Capobianchi MR, Lepfoundzou AD, et al. First reported chikungunya fever outbreak in the republic of Congo, 2011. PloS one 2014; 9:e115938; PMID:25541718; http://dx.doi.org/10.1371/journal.pone.0115938
   PubMed Web of Science ®Google Scholar
• Chretien JP, Anyamba A, Bedno SA, Breiman RF, Sang R, Sergon K, Powers AM, Onyango CO, Small J, Tucker CJ, et al. Drought-associated chikungunya emergence along coastal East Africa. Am J Trop Med Hyg 2007; 76:405-7; PMID:17360859
   PubMed Web of Science ®Google Scholar
• Economopoulou A, Dominguez M, Helynck B, Sissoko D, Wichmann O, Quenel P, Germonneau P, Quatresous I. Atypical Chikungunya virus infections: clinical manifestations, mortality and risk factors for severe disease during the 2005-2006 outbreak on Reunion. Epidemiol Infect 2009; 137:534-41; PMID:18694529; http://dx.doi.org/10.1017/S0950268808001167
   PubMed Web of Science ®Google Scholar
• Mudur G. Failure to control mosquitoes has led to two fever epidemics in India. BMJ 2006; 333:773; PMID:17038726; http://dx.doi.org/10.1136/bmj.333.7572.773-c
   PubMedGoogle Scholar
• Gould EA, Gallian P, De Lamballerie X, Charrel RN. First cases of autochthonous dengue fever and chikungunya fever in France: from bad dream to reality! Clin Microbiol Infect 2010; 16:1702-4; PMID:21040155; http://dx.doi.org/10.1111/j.1469-0691.2010.03386.x
   PubMed Web of Science ®Google Scholar
• Rezza G, Nicoletti L, Angelini R, Romi R, Finarelli AC, Panning M, Cordioli P, Fortuna C, Boros S, Magurano F, et al. Infection with chikungunya virus in Italy: an outbreak in a temperate region. Lancet 2007; 370:1840-6; PMID:18061059; http://dx.doi.org/10.1016/S0140-6736(07)61779-6
   PubMed Web of Science ®Google Scholar
• Paty MC, Six C, Charlet F, Heuze G, Cochet A, Wiegandt A, Chappert JL, Dejour-Salamanca D, Guinard A, Soler P, et al. Large number of imported chikungunya cases in mainland France, 2014: a challenge for surveillance and response. Euro Surveill 2014; 19:20856; PMID:25060572
   PubMedGoogle Scholar
• Halstead SB. Reappearance of chikungunya, formerly called dengue, in the americas. Emerg Infect Dis 2015; 21:557-61; PMID:25816211; http://dx.doi.org/10.3201/eid2104.141723
   PubMed Web of Science ®Google Scholar
• Weaver SC. Arrival of chikungunya virus in the new world: prospects for spread and impact on public health. PLoS Negl Trop Dis 2014; 8:e2921; PMID:24967777; http://dx.doi.org/10.1371/journal.pntd.0002921
   PubMed Web of Science ®Google Scholar
• Tsetsarkin KA, Chen R, Leal G, Forrester N, Higgs S, Huang J, Weaver SC. Chikungunya virus emergence is constrained in Asia by lineage-specific adaptive landscapes. Proc Natl Acad Sci U S A 2011; 108:7872-7; PMID:21518887; http://dx.doi.org/10.1073/pnas.1018344108
   PubMed Web of Science ®Google Scholar
• CDC. 2015 provisional data for the United States. 2015; http://www.cdc.gov/chikungunya/geo/united-states-2015.html (accessed August 26th, 2015).
   Google Scholar
• Zheng K, Li J, Zhang Q, Liang M, Li C, Lin M, Huang J, Li H, Xiang D, Wang N, et al. Genetic analysis of chikungunya viruses imported to mainland China in 2008. Virol J 2010; 7:8; PMID:20078896; http://dx.doi.org/10.1186/1743-422X-7-8
   PubMed Web of Science ®Google Scholar
• Fros JJ, Liu WJ, Prow NA, Geertsema C, Ligtenberg M, Vanlandingham DL, Schnettler E, Vlak JM, Suhrbier A, Khromykh AA, et al. Chikungunya virus nonstructural protein 2 inhibits type I/II interferon-stimulated JAK-STAT signaling. J Virol 2010; 84:10877-87; PMID:20686047; http://dx.doi.org/10.1128/JVI.00949-10
   PubMed Web of Science ®Google Scholar
• Dudha N, Rana J, Rajasekharan S, Gabrani R, Gupta A, Chaudhary VK, Gupta S. Host-pathogen interactome analysis of Chikungunya virus envelope proteins E1 and E2. Virus Genes 2015; 50:200-9; PMID:25563600; http://dx.doi.org/10.1007/s11262-014-1161-x
   PubMed Web of Science ®Google Scholar
• Uchime O, Fields W, Kielian M. The role of E3 in pH protection during alphavirus assembly and exit. J Virol 2013; 87:10255-62; PMID:23864626; http://dx.doi.org/10.1128/JVI.01507-13
   PubMed Web of Science ®Google Scholar
• Choi HK, Tong L, Minor W, Dumas P, Boege U, Rossmann MG, Wengler G. Structure of Sindbis virus core protein reveals a chymotrypsin-like serine proteinase and the organization of the virion. Nature 1991; 354:37-43; PMID:1944569; http://dx.doi.org/10.1038/354037a0
   PubMed Web of Science ®Google Scholar
• Hallengard D, Kakoulidou M, Lulla A, Kummerer BM, Johansson DX, Mutso M, Lulla V, Fazakerley JK, Roques P, Le Grand R, et al. Novel attenuated Chikungunya vaccine candidates elicit protective immunity in C57BL/6 mice. J Virol 2014; 88:2858-66; PMID:24371047; http://dx.doi.org/10.1128/JVI.03453-13
   PubMed Web of Science ®Google Scholar
• Saisawang C, Sillapee P, Sinsirimongkol K, Ubol S, Smith DR, Ketterman AJ. Full length and protease domain activity of Chikungunya virus nsP2 differ from other alphavirus nsP2 proteases in recognition of small peptide substrates. Biosci Rep 2015; 35
   Web of Science ®Google Scholar
• Sam IC, Loong SK, Michael JC, Chua CL, Wan Sulaiman WY, Vythilingam I, Chan SY, Chiam CW, Yeong YS, AbuBakar S, et al. Genotypic and phenotypic characterization of Chikungunya virus of different genotypes from Malaysia. PloS one 2012; 7:e50476; PMID:23209750; http://dx.doi.org/10.1371/journal.pone.0050476
   PubMedGoogle Scholar
• Volk SM, Chen R, Tsetsarkin KA, Adams AP, Garcia TI, Sall AA, Nasar F, Schuh AJ, Holmes EC, Higgs S, et al. Genome-scale phylogenetic analyses of chikungunya virus reveal independent emergences of recent epidemics and various evolutionary rates. J Virol 2010; 84:6497-504; PMID:20410280; http://dx.doi.org/10.1128/JVI.01603-09
   PubMed Web of Science ®Google Scholar
• Tsetsarkin KA, Vanlandingham DL, McGee CE, Higgs S. A single mutation in chikungunya virus affects vector specificity and epidemic potential. PLoS Pathog 2007; 3:e201; PMID:18069894; http://dx.doi.org/10.1371/journal.ppat.0030201
   PubMed Web of Science ®Google Scholar
• ECDC. Aedes albopictus. 2014; http://ecdc.europa.eu/en/healthtopics/vectors/mosquitoes/Pages/aedes-albopictus.aspx (accessed July 10th, 2015)
   Google Scholar
• Ribeiro JM, Rossignol PA, Spielman A. Role of mosquito saliva in blood vessel location. J Exp Biol 1984; 108:1-7; PMID:6707570
   PubMed Web of Science ®Google Scholar
• Ribeiro JM, Arca B, Lombardo F, Calvo E, Phan VM, Chandra PK, Wikel SK. An annotated catalogue of salivary gland transcripts in the adult female mosquito, Aedes aegypti. BMC Genomics 2007; 8:6; PMID:17204158; http://dx.doi.org/10.1186/1471-2164-8-6
   PubMed Web of Science ®Google Scholar
• Maharaj PD, Widen SG, Huang J, Wood TG, Thangamani S. Discovery of mosquito saliva microRNAs during CHIKV infection. PLoS Negl Trop Dis 2015; 9:e0003386; PMID:25612225; http://dx.doi.org/10.1371/journal.pntd.0003386
   PubMed Web of Science ®Google Scholar
• Puiprom O, Morales Vargas RE, Potiwat R, Chaichana P, Ikuta K, Ramasoota P, Okabayashi T. Characterization of chikungunya virus infection of a human keratinocyte cell line: role of mosquito salivary gland protein in suppressing the host immune response. Infect Genet Evol 2013; 17:210-5; PMID:23583544; http://dx.doi.org/10.1016/j.meegid.2013.04.005
   PubMed Web of Science ®Google Scholar
• Schneider BS, Higgs S. The enhancement of arbovirus transmission and disease by mosquito saliva is associated with modulation of the host immune response. Trans R Soc Trop Med Hyg 2008; 102:400-8; PMID:18342898; http://dx.doi.org/10.1016/j.trstmh.2008.01.024
   PubMed Web of Science ®Google Scholar
• Calvo E, Mans BJ, Andersen JF, Ribeiro JM. Function and evolution of a mosquito salivary protein family. J Biol Chem 2006; 281:1935-42; PMID:16301315; http://dx.doi.org/10.1074/jbc.M510359200
   PubMed Web of Science ®Google Scholar
• Thangamani S, Higgs S, Ziegler S, Vanlandingham D, Tesh R, Wikel S. Host immune response to mosquito-transmitted chikungunya virus differs from that elicited by needle inoculated virus. PloS one 2010; 5:e12137; PMID:20711354; http://dx.doi.org/10.1371/journal.pone.0012137
   PubMedGoogle Scholar
• Schilte C, Couderc T, Chretien F, Sourisseau M, Gangneux N, Guivel-Benhassine F, Kraxner A, Tschopp J, Higgs S, Michault A, et al. Type I IFN controls chikungunya virus via its action on nonhematopoietic cells. J Exp Med 2010; 207:429-42; PMID:20123960; http://dx.doi.org/10.1084/jem.20090851
   PubMed Web of Science ®Google Scholar
• Her Z, Malleret B, Chan M, Ong EK, Wong SC, Kwek DJ, Tolou H, Lin RT, Tambyah PA, Renia L, et al. Active infection of human blood monocytes by Chikungunya virus triggers an innate immune response. J Immunol 2010; 184:5903-13; http://dx.doi.org/10.4049/jimmunol.0904181
   PubMed Web of Science ®Google Scholar
• Sourisseau M, Schilte C, Casartelli N, Trouillet C, Guivel-Benhassine F, Rudnicka D, Sol-Foulon N, Le Roux K, Prevost MC, Fsihi H, et al. Characterization of reemerging chikungunya virus. PLoS Pathog 2007; 3:e89; PMID:17604450; http://dx.doi.org/10.1371/journal.ppat.0030089
   PubMed Web of Science ®Google Scholar
• Couderc T, Chretien F, Schilte C, Disson O, Brigitte M, Guivel-Benhassine F, Touret Y, Barau G, Cayet N, Schuffenecker I, et al. A mouse model for Chikungunya: young age and inefficient type-I interferon signaling are risk factors for severe disease. PLoS Pathog 2008; 4:e29; PMID:18282093; http://dx.doi.org/10.1371/journal.ppat.0040029
   PubMed Web of Science ®Google Scholar
• Kam YW, Ong EK, Renia L, Tong JC, Ng LF. Immuno-biology of Chikungunya and implications for disease intervention. Microbes and infection / Institut Pasteur 2009; 11:1186-96; PMID:19737625; http://dx.doi.org/10.1016/j.micinf.2009.09.003
   PubMed Web of Science ®Google Scholar
• Chow A, Her Z, Ong EK, Chen JM, Dimatatac F, Kwek DJ, Barkham T, Yang H, Renia L, Leo YS, et al. Persistent arthralgia induced by Chikungunya virus infection is associated with interleukin-6 and granulocyte macrophage colony-stimulating factor. J Infect Dis 2011; 203:149-57; PMID:21288813; http://dx.doi.org/10.1093/infdis/jiq042
   PubMed Web of Science ®Google Scholar
• Gasque P, Couderc T, Lecuit M, Roques P, Ng LF. Chikungunya virus pathogenesis and immunity. Vector Borne Zoonotic Dis 2015; 15:241-9; PMID:25897810; http://dx.doi.org/10.1089/vbz.2014.1710
   PubMed Web of Science ®Google Scholar
• Wauquier N, Becquart P, Nkoghe D, Padilla C, Ndjoyi-Mbiguino A, Leroy EM. The acute phase of Chikungunya virus infection in humans is associated with strong innate immunity and T CD8 cell activation. J Infect Dis 2011; 204:115-23; PMID:21628665; http://dx.doi.org/10.1093/infdis/jiq006
   PubMed Web of Science ®Google Scholar
• Schwartz O, Albert ML. Biology and pathogenesis of chikungunya virus. Nat Rev Microbiol 2010; 8:491-500; PMID:20551973; http://dx.doi.org/10.1038/nrmicro2368
   PubMed Web of Science ®Google Scholar
• Labadie K, Larcher T, Joubert C, Mannioui A, Delache B, Brochard P, Guigand L, Dubreil L, Lebon P, Verrier B, et al. Chikungunya disease in nonhuman primates involves long-term viral persistence in macrophages. J Clin Investig 2010; 120:894-906; PMID:20179353; http://dx.doi.org/10.1172/JCI40104
   PubMed Web of Science ®Google Scholar
• Selvamani SP, Mishra R, Singh SK. Chikungunya virus exploits miR-146a to regulate NF-kappaB pathway in human synovial fibroblasts. PloS one 2014; 9:e103624; PMID:25083878; http://dx.doi.org/10.1371/journal.pone.0103624
   PubMedGoogle Scholar
• Chen W, Foo SS, Rulli NE, Taylor A, Sheng KC, Herrero LJ, Herring BL, Lidbury BA, Li RW, Walsh NC, et al. Arthritogenic alphaviral infection perturbs osteoblast function and triggers pathologic bone loss. Proc Natl Acad Sci U S A 2014; 111:6040-5; PMID:24733914; http://dx.doi.org/10.1073/pnas.1318859111
   PubMed Web of Science ®Google Scholar
• Noret M, Herrero L, Rulli N, Rolph M, Smith PN, Li RW, Roques P, Gras G, Mahalingam S. Interleukin 6, RANKL, and osteoprotegerin expression by chikungunya virus-infected human osteoblasts. J Infect Dis 2012; 206:455-7: 7-9; http://dx.doi.org/10.1093/infdis/jis368
   PubMed Web of Science ®Google Scholar
• Brandler S, Ruffie C, Combredet C, Brault JB, Najburg V, Prevost MC, Habel A, Tauber E, Despres P, Tangy F. A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus. Vaccine 2013; 31:3718-25; PMID:23742993; http://dx.doi.org/10.1016/j.vaccine.2013.05.086
   PubMed Web of Science ®Google Scholar
• Brehin AC, Rubrecht L, Navarro-Sanchez ME, Marechal V, Frenkiel MP, Lapalud P, Laune D, Sall AA, Despres P. Production and characterization of mouse monoclonal antibodies reactive to Chikungunya envelope E2 glycoprotein. Virology 2008; 371:185-95; PMID:17949772; http://dx.doi.org/10.1016/j.virol.2007.09.028
   PubMed Web of Science ®Google Scholar
• Pal P, Dowd KA, Brien JD, Edeling MA, Gorlatov S, Johnson S, Lee I, Akahata W, Nabel GJ, Richter MK, et al. Development of a highly protective combination monoclonal antibody therapy against Chikungunya virus. PLoS Pathog 2013; 9:e1003312; PMID:23637602; http://dx.doi.org/10.1371/journal.ppat.1003312
   PubMed Web of Science ®Google Scholar
• Couderc T, Khandoudi N, Grandadam M, Visse C, Gangneux N, Bagot S, Prost JF, Lecuit M. Prophylaxis and therapy for Chikungunya virus infection. J Infect Dis 2009; 200:516-23; PMID:19572805; http://dx.doi.org/10.1086/600381
   PubMed Web of Science ®Google Scholar
• Rudd PA, Wilson J, Gardner J, Larcher T, Babarit C, Le TT, Anraku I, Kumagai Y, Loo YM, Gale M, Jr., et al. Interferon response factors 3 and 7 protect against Chikungunya virus hemorrhagic fever and shock. J Virol 2012; 86:9888-98; PMID:22761364; http://dx.doi.org/10.1128/JVI.00956-12
   PubMed Web of Science ®Google Scholar
• Munoz-Jordan JL. Subversion of interferon by dengue virus. Curr Top Microbiol Immunol 2010; 338:35-44; PMID:19802576
   PubMed Web of Science ®Google Scholar
• Meylan E, Tschopp J. Toll-like receptors and RNA helicases: two parallel ways to trigger antiviral responses. Mol Cell 2006; 22:561-9; PMID:16762830; http://dx.doi.org/10.1016/j.molcel.2006.05.012
   PubMed Web of Science ®Google Scholar
• Morrison J, Aguirre S, Fernandez-Sesma A. Innate immunity evasion by Dengue virus. Viruses 2012; 4:397-413; PMID:22590678; http://dx.doi.org/10.3390/v4030397
   PubMed Web of Science ®Google Scholar
• Rodriguez-Madoz JR, Belicha-Villanueva A, Bernal-Rubio D, Ashour J, Ayllon J, Fernandez-Sesma A. Inhibition of the type I interferon response in human dendritic cells by dengue virus infection requires a catalytically active NS2B3 complex. J Virol 2010; 84:9760-74; PMID:20660196; http://dx.doi.org/10.1128/JVI.01051-10
   PubMed Web of Science ®Google Scholar
• Hoang LT, Lynn DJ, Henn M, Birren BW, Lennon NJ, Le PT, Duong KT, Nguyen TT, Mai LN, Farrar JJ, et al. The early whole-blood transcriptional signature of dengue virus and features associated with progression to dengue shock syndrome in Vietnamese children and young adults. J Virol 2010; 84:12982-94; PMID:20943967; http://dx.doi.org/10.1128/JVI.01224-10
   PubMed Web of Science ®Google Scholar
• Ramirez-Ronda CH, Garcia CD. Dengue in the Western Hemisphere. Infect Dis Clin North Am 1994; 8:107-28; PMID:7912702
   PubMed Web of Science ®Google Scholar
• Chahar HS, Bao X, Casola A. Exosomes and Their Role in the Life Cycle and Pathogenesis of RNA Viruses. Viruses 2015; 7:3204-25; PMID:26102580; http://dx.doi.org/10.3390/v7062770
   PubMed Web of Science ®Google Scholar
• Brass AL, Huang IC, Benita Y, John SP, Krishnan MN, Feeley EM, Ryan BJ, Weyer JL, van der Weyden L, Fikrig E, et al. The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus. Cell 2009; 139:1243-54; PMID:20064371; http://dx.doi.org/10.1016/j.cell.2009.12.017
   PubMed Web of Science ®Google Scholar
• Zhu X, He Z, Yuan J, Wen W, Huang X, Hu Y, Lin C, Pan J, Li R, Deng H, et al. IFITM3-containing exosome as a novel mediator for anti-viral response in dengue virus infection. Cell Microbiol 2015; 17:105-18; PMID:25131332; http://dx.doi.org/10.1111/cmi.12339
   PubMed Web of Science ®Google Scholar
• Fink K, Ng C, Nkenfou C, Vasudevan SG, van Rooijen N, Schul W. Depletion of macrophages in mice results in higher dengue virus titers and highlights the role of macrophages for virus control. Eur J Immunol 2009; 39:2809-21; PMID:19637226; http://dx.doi.org/10.1002/eji.200939389
   PubMed Web of Science ®Google Scholar
• Kalantri SP, Joshi R, Riley LW. Chikungunya epidemic: an Indian perspective. Natl Med J India 2006; 19:315-22; PMID:17343016
   PubMed Web of Science ®Google Scholar
• Yoon IK, Alera MT, Lago CB, Tac-An IA, Villa D, Fernandez S, Thaisomboonsuk B, Klungthong C, Levy JW, Velasco JM, et al. High rate of subclinical chikungunya virus infection and association of neutralizing antibody with protection in a prospective cohort in the Philippines. PLoS Negl Trop Dis 2015; 9:e0003764; PMID:25951202; http://dx.doi.org/10.1371/journal.pntd.0003764
   PubMed Web of Science ®Google Scholar
• Staikowsky F, Talarmin F, Grivard P, Souab A, Schuffenecker I, Le Roux K, Lecuit M, Michault A. Prospective study of Chikungunya virus acute infection in the Island of La Reunion during the 2005-2006 outbreak. PloS one 2009; 4:e7603; PMID:19893613; http://dx.doi.org/10.1371/journal.pone.0007603
   PubMedGoogle Scholar
• Reddy V, Mani RS, Desai A, Ravi V. Correlation of plasma viral loads and presence of Chikungunya IgM antibodies with cytokine/chemokine levels during acute Chikungunya virus infection. J Med Virol 2014; 86:1393-401; PMID:24523146; http://dx.doi.org/10.1002/jmv.23875
   PubMed Web of Science ®Google Scholar
• Gerardin P, Fianu A, Michault A, Mussard C, Boussaid K, Rollot O, Grivard P, Kassab S, Bouquillard E, Borgherini G, et al. Predictors of Chikungunya rheumatism: a prognostic survey ancillary to the TELECHIK cohort study. Arthritis Res Ther 2013; 15:R9; PMID:23302155; http://dx.doi.org/10.1186/ar4137
   PubMed Web of Science ®Google Scholar
• Simon F, Parola P, Grandadam M, Fourcade S, Oliver M, Brouqui P, Hance P, Kraemer P, Ali Mohamed A, de Lamballerie X, et al. Chikungunya infection: an emerging rheumatism among travelers returned from Indian Ocean islands. Report of 47 cases. Medicine 2007; 86:123-37; PMID:17505252; http://dx.doi.org/10.1097/MD/0b013e31806010a5
   PubMed Web of Science ®Google Scholar
• Taubitz W, Cramer JP, Kapaun A, Pfeffer M, Drosten C, Dobler G, Burchard GD, Loscher T. Chikungunya fever in travelers: clinical presentation and course. Clin Infect Dis 2007; 45:e1-4; PMID:17554689; http://dx.doi.org/10.1086/518701
   PubMed Web of Science ®Google Scholar
• Mohan A. Chikungunya fever: clinical manifestations & management. Indian J Med Res 2006; 124:471-4; PMID:17213512
   PubMed Web of Science ®Google Scholar
• Rohatgi A, Corbo JC, Monte K, Higgs S, Vanlandingham DL, Kardon G, Lenschow DJ. Infection of myofibers contributes to increased pathogenicity during infection with an epidemic strain of chikungunya virus. J Virol 2014; 88:2414-25; PMID:24335291; http://dx.doi.org/10.1128/JVI.02716-13
   PubMed Web of Science ®Google Scholar
• Josseran L, Paquet C, Zehgnoun A, Caillere N, Le Tertre A, Solet JL, Ledrans M. Chikungunya disease outbreak, Reunion Island. Emerg Infect Dis 2006; 12:1994-5; PMID:17354339; http://dx.doi.org/10.3201/eid1212.060710
   PubMed Web of Science ®Google Scholar
• Renault P, Solet JL, Sissoko D, Balleydier E, Larrieu S, Filleul L, Lassalle C, Thiria J, Rachou E, de Valk H, et al. A major epidemic of chikungunya virus infection on Reunion Island, France, 2005-2006. Am J Trop Med Hyg 2007; 77:727-31; PMID:17978079
   PubMed Web of Science ®Google Scholar
• Schilte C, Staikowsky F, Couderc T, Madec Y, Carpentier F, Kassab S, Albert ML, Lecuit M, Michault A. Chikungunya virus-associated long-term arthralgia: a 36-month prospective longitudinal study. PLoS Negl Trop Dis 2013; 7:e2137; PMID:23556021; http://dx.doi.org/10.1371/journal.pntd.0002137
   PubMed Web of Science ®Google Scholar
• Simon F, Javelle E, Gasque P. Chikungunya Virus Infections. N Engl J Med 2015; 373:93-4; PMID:26132957; http://dx.doi.org/10.1056/NEJMc1505501
   PubMed Web of Science ®Google Scholar
• Chen W, Foo SS, Sims NA, Herrero LJ, Walsh NC, Mahalingam S. Arthritogenic alphaviruses: new insights into arthritis and bone pathology. Trends Microbiol 2015; 23:35-43; PMID:25449049; http://dx.doi.org/10.1016/j.tim.2014.09.005
   PubMed Web of Science ®Google Scholar
• Ozden S, Huerre M, Riviere JP, Coffey LL, Afonso PV, Mouly V, de Monredon J, Roger JC, El Amrani M, Yvin JL, et al. Human muscle satellite cells as targets of Chikungunya virus infection. PloS one 2007; 2:e527; PMID:17565380; http://dx.doi.org/10.1371/journal.pone.0000527
   PubMed Web of Science ®Google Scholar
• Hoarau JJ, Jaffar Bandjee MC, Krejbich Trotot P, Das T, Li-Pat-Yuen G, Dassa B, Denizot M, Guichard E, Ribera A, Henni T, et al. Persistent chronic inflammation and infection by Chikungunya arthritogenic alphavirus in spite of a robust host immune response. J Immunol 2010; 184:5914-27; http://dx.doi.org/10.4049/jimmunol.0900255
   PubMed Web of Science ®Google Scholar
• Pialoux G, Gauzere BA, Jaureguiberry S, Strobel M. Chikungunya, an epidemic arbovirosis. Lancet Infect Dis 2007; 7:319-27; PMID:17448935; http://dx.doi.org/10.1016/S1473-3099(07)70107-X
   PubMed Web of Science ®Google Scholar
• Sudeep AB, Parashar D. Chikungunya: an overview. J Biosci 2008; 33:443-9; PMID:19208970; http://dx.doi.org/10.1007/s12038-008-0063-2
   PubMed Web of Science ®Google Scholar
• Chevillon C, Briant L, Renaud F, Devaux C. The Chikungunya threat: an ecological and evolutionary perspective. Trends Microbiol 2008; 16:80-8; PMID:18191569; http://dx.doi.org/10.1016/j.tim.2007.12.003
   PubMed Web of Science ®Google Scholar
• Magurano F, Zammarchi L, Baggieri M, Fortuna C, Farese A, Benedetti E, Fiorentini C, Rezza G, Nicoletti L, Bartoloni A. Chikungunya from the Caribbean: the importance of appropriate laboratory tests to confirm the diagnosis. Vector Borne Zoonotic Dis 2015; 15:258-60; PMID:25897812; http://dx.doi.org/10.1089/vbz.2014.1724
   PubMed Web of Science ®Google Scholar
• Foissac M, Javelle E, Ray S, Guerin B, Simon F. Post-Chikungunya rheumatoid arthritis, Saint Martin. Emerg Infect Dis 2015; 21:530-2; PMID:25695499; http://dx.doi.org/10.3201/eid2103.141397
   PubMed Web of Science ®Google Scholar
• Kam YW, Lee WW, Simarmata D, Harjanto S, Teng TS, Tolou H, Chow A, Lin RT, Leo YS, Renia L, et al. Longitudinal analysis of the human antibody response to Chikungunya virus infection: implications for serodiagnosis and vaccine development. J Virol 2012; 86:13005-15; PMID:23015702; http://dx.doi.org/10.1128/JVI.01780-12
   PubMed Web of Science ®Google Scholar
• Panning M, Grywna K, van Esbroeck M, Emmerich P, Drosten C. Chikungunya fever in travelers returning to Europe from the Indian Ocean region, 2006. Emerg Infect Dis 2008; 14:416-22; PMID:18325256; http://dx.doi.org/10.3201/eid1403.070906
   PubMed Web of Science ®Google Scholar
• Pierro A, Rossini G, Gaibani P, Finarelli AC, Moro ML, Landini MP, Sambri V. Persistence of anti-chikungunya virus-specific antibodies in a cohort of patients followed from the acute phase of infection after the 2007 outbreak in Italy. New Microbes New Infect 2015; 7:23-5; PMID:26106482; http://dx.doi.org/10.1016/j.nmni.2015.04.002
   PubMedGoogle Scholar
• Borgherini G, Poubeau P, Jossaume A, Gouix A, Cotte L, Michault A, Arvin-Berod C, Paganin F. Persistent arthralgia associated with chikungunya virus: a study of 88 adult patients on reunion island. Clin Infect Dis 2008; 47:469-75; PMID:18611153; http://dx.doi.org/10.1086/590003
   PubMed Web of Science ®Google Scholar
• de Andrade DC, Jean S, Clavelou P, Dallel R, Bouhassira D. Chronic pain associated with the Chikungunya Fever: long lasting burden of an acute illness. BMC Infect Dis 2010; 10:31; PMID:20170492; http://dx.doi.org/10.1186/1471-2334-10-31
   PubMed Web of Science ®Google Scholar
• WHO. Guidelines on Clinical Management of Chikungunya Fever. 2008; http://www.wpro.who.int/mvp/topics/ntd/Clinical_Mgnt_Chikungunya_WHO_SEARO.pdf (accessed August 25th, 2015)
   Google Scholar
• Briolant S, Garin D, Scaramozzino N, Jouan A, Crance JM. In vitro inhibition of Chikungunya and Semliki Forest viruses replication by antiviral compounds: synergistic effect of interferon-alpha and ribavirin combination. Antiviral Res 2004; 61:111-7; PMID:14670584; http://dx.doi.org/10.1016/j.antiviral.2003.09.005
   PubMed Web of Science ®Google Scholar
• Rothan HA, Bahrani H, Mohamed Z, Teoh TC, Shankar EM, Rahman NA, Yusof R. A combination of doxycycline and ribavirin alleviated chikungunya infection. PloS one 2015; 10:e0126360; PMID:25970853; http://dx.doi.org/10.1371/journal.pone.0126360
   PubMed Web of Science ®Google Scholar
• De Lamballerie X, Boisson V, Reynier JC, Enault S, Charrel RN, Flahault A, Roques P, Le Grand R. On chikungunya acute infection and chloroquine treatment. Vector Borne Zoonotic Dis 2008; 8:837-9; PMID:18620511; http://dx.doi.org/10.1089/vbz.2008.0049
   PubMed Web of Science ®Google Scholar
• Ganu MA, Ganu AS. Post-chikungunya chronic arthritis–our experience with DMARDs over two year follow up. J Assoc Physicians India 2011; 59:83-6; PMID:21751641
   PubMedGoogle Scholar
• Ribera A, Degasne I, Jaffar Bandjee MC, Gasque P. ; Chronic rheumatic manifestations following chikungunya virus infection: clinical description and therapeutic considerations. Med Trop 2012; 72 Spec No:83-5; PMID:22693935
   PubMedGoogle Scholar
• Bouquillard E, Combe B. A report of 21 cases of rheumatoid arthritis following Chikungunya fever. A mean follow-up of two years. Joint Bone Spine 2009; 76:654-7; PMID:19945329; http://dx.doi.org/10.1016/j.jbspin.2009.08.005
   PubMed Web of Science ®Google Scholar
• Javelle E, Ribera A, Degasne I, Gauzere BA, Marimoutou C, Simon F. Specific management of post-chikungunya rheumatic disorders: a retrospective study of 159 cases in Reunion Island from 2006-2012. PLoS Negl Trop Dis 2015; 9:e0003603; PMID:25760632; http://dx.doi.org/10.1371/journal.pntd.0003603
   PubMedGoogle Scholar
• Delang L, Segura Guerrero N, Tas A, Querat G, Pastorino B, Froeyen M, Dallmeier K, Jochmans D, Herdewijn P, Bello F, et al. Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral. J Antimicrob Chemother 2014; 69:2770-84; PMID:24951535; http://dx.doi.org/10.1093/jac/dku209
   PubMed Web of Science ®Google Scholar
• Dash PK, Tiwari M, Santhosh SR, Parida M, Lakshmana Rao PV. RNA interference mediated inhibition of Chikungunya virus replication in mammalian cells. Biochem Biophys Res Commun 2008; 376:718-22; PMID:18805396; http://dx.doi.org/10.1016/j.bbrc.2008.09.040
   PubMed Web of Science ®Google Scholar
• Lam S, Chen KC, Ng MM, Chu JJ. Expression of plasmid-based shRNA against the E1 and nsP1 genes effectively silenced Chikungunya virus replication. PloS one 2012; 7:e46396; PMID:23056297; http://dx.doi.org/10.1371/journal.pone.0046396
   PubMed Web of Science ®Google Scholar
• Fong RH, Banik SS, Mattia K, Barnes T, Tucker D, Liss N, Lu K, Selvarajah S, Srinivasan S, Mabila M, et al. Exposure of epitope residues on the outer face of the chikungunya virus envelope trimer determines antibody neutralizing efficacy. J Virol 2014; 88:14364-79; PMID:25275138; http://dx.doi.org/10.1128/JVI.01943-14
   PubMed Web of Science ®Google Scholar
• Warter L, Lee CY, Thiagarajan R, Grandadam M, Lebecque S, Lin RT, Bertin-Maghit S, Ng LF, Abastado JP, Despres P, et al. Chikungunya virus envelope-specific human monoclonal antibodies with broad neutralization potency. J Immunol 2011; 186:3258-64; http://dx.doi.org/10.4049/jimmunol.1003139
   PubMed Web of Science ®Google Scholar
• Lee CY, Kam YW, Fric J, Malleret B, Koh EG, Prakash C, Huang W, Lee WW, Lin C, Lin RT, et al. Chikungunya virus neutralization antigens and direct cell-to-cell transmission are revealed by human antibody-escape mutants. PLoS Pathog 2011; 7:e1002390; PMID:22144891; http://dx.doi.org/10.1371/journal.ppat.1002390
   PubMed Web of Science ®Google Scholar
• Fric J, Bertin-Maghit S, Wang CI, Nardin A, Warter L. Use of human monoclonal antibodies to treat Chikungunya virus infection. J Infect Dis 2013; 207:319-22; PMID:23125446; http://dx.doi.org/10.1093/infdis/jis674
   PubMed Web of Science ®Google Scholar
• Masrinoul P, Puiprom O, Tanaka A, Kuwahara M, Chaichana P, Ikuta K, Ramasoota P, Okabayashi T. Monoclonal antibody targeting chikungunya virus envelope 1 protein inhibits virus release. Virology 2014; 464-465:111-7; PMID:25063884
   PubMed Web of Science ®Google Scholar
• Goh LY, Hobson-Peters J, Prow NA, Gardner J, Bielefeldt-Ohmann H, Pyke AT, Suhrbier A, Hall RA. Neutralizing monoclonal antibodies to the E2 protein of chikungunya virus protects against disease in a mouse model. Clin Immunol 2013; 149:487-97; PMID:24239837; http://dx.doi.org/10.1016/j.clim.2013.10.004
   PubMed Web of Science ®Google Scholar
• Selvarajah S, Sexton NR, Kahle KM, Fong RH, Mattia KA, Gardner J, Lu K, Liss NM, Salvador B, Tucker DF, et al. A neutralizing monoclonal antibody targeting the acid-sensitive region in chikungunya virus E2 protects from disease. PLoS Negl Trop Dis 2013; 7:e2423; PMID:24069479; http://dx.doi.org/10.1371/journal.pntd.0002423
   PubMed Web of Science ®Google Scholar
• Goh LY, Hobson-Peters J, Prow NA, Gardner J, Bielefeldt-Ohmann H, Suhrbier A, Hall RA. Monoclonal antibodies specific for the capsid protein of chikungunya virus suitable for multiple applications. J Gen Virol 2015; 96:507-12; PMID:25480927; http://dx.doi.org/10.1099/jgv.0.000002
   PubMed Web of Science ®Google Scholar
• Hansel TT, Kropshofer H, Singer T, Mitchell JA, George AJ. The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov 2010; 9:325-38; PMID:20305665; http://dx.doi.org/10.1038/nrd3003
   PubMed Web of Science ®Google Scholar
• CDC. CHIKUNGUNYA information for vector control programs. 2015; http://www.cdc.gov/chikungunya/pdfs/CHIKV_VectorControl.pdf (accessed July 9th, 2015)
   Google Scholar
• Lang J, Wood SC. Development of orphan vaccines: an industry perspective. Emerg Infect Dis 1999; 5:749-56; PMID:10603207; http://dx.doi.org/10.3201/eid0506.990602
   PubMed Web of Science ®Google Scholar
• Kumar CJ, Baboo CA, Krishnan BU, Kumar A, Joy S, Jose T, Philip A, Sambasivaiah K, Hegde BM. The socioeconomic impact of the chikungunya viral epidemic in India. Open Med 2007; 1:e150-2; PMID:21673944
   PubMedGoogle Scholar
• Seyler T, Hutin Y, Ramanchandran V, Ramakrishnan R, Manickam P, Murhekar M. Estimating the burden of disease and the economic cost attributable to chikungunya, Andhra Pradesh, India, 2005-2006. Trans R Soc Trop Med Hyg 2010; 104:133-8; PMID:19709705; http://dx.doi.org/10.1016/j.trstmh.2009.07.014
   PubMed Web of Science ®Google Scholar
• Soumahoro MK, Boelle PY, Gauzere BA, Atsou K, Pelat C, Lambert B, La Ruche G, Gastellu-Etchegorry M, Renault P, Sarazin M, et al. The Chikungunya epidemic on La Reunion Island in 2005-2006: a cost-of-illness study. PLoS Negl Trop Dis 2011; 5:e1197; PMID:21695162; http://dx.doi.org/10.1371/journal.pntd.0001197
   PubMed Web of Science ®Google Scholar
• Vazquez-Prokopec GM, Chaves LF, Ritchie SA, Davis J, Kitron U. Unforeseen costs of cutting mosquito surveillance budgets. PLoS Negl Trop Dis 2010; 4:e858; PMID:21049010; http://dx.doi.org/10.1371/journal.pntd.0000858
   PubMedGoogle Scholar
• Roy CJ, Adams AP, Wang E, Plante K, Gorchakov R, Seymour RL, Vinet-Oliphant H, Weaver SC. Chikungunya vaccine candidate is highly attenuated and protects nonhuman primates against telemetrically monitored disease following a single dose. J Infect Dis 2014; 209:1891-9; PMID:24403555; http://dx.doi.org/10.1093/infdis/jiu014
   PubMed Web of Science ®Google Scholar
• Hoke CH, Jr., Pace-Templeton J, Pittman P, Malinoski FJ, Gibbs P, Ulderich T, Mathers M, Fogtman B, Glass P, Vaughn DW. US Military contributions to the global response to pandemic chikungunya. Vaccine 2012; 30:6713-20; PMID:22940380; http://dx.doi.org/10.1016/j.vaccine.2012.08.025
   PubMed Web of Science ®Google Scholar
• Wang E, Volkova E, Adams AP, Forrester N, Xiao SY, Frolov I, Weaver SC. Chimeric alphavirus vaccine candidates for chikungunya. Vaccine 2008; 26:5030-9; PMID:18692107; http://dx.doi.org/10.1016/j.vaccine.2008.07.054
   PubMed Web of Science ®Google Scholar
• Wang D, Suhrbier A, Penn-Nicholson A, Woraratanadharm J, Gardner J, Luo M, Le TT, Anraku I, Sakalian M, Einfeld D, et al. A complex adenovirus vaccine against chikungunya virus provides complete protection against viraemia and arthritis. Vaccine 2011; 29:2803-9; PMID:21320541; http://dx.doi.org/10.1016/j.vaccine.2011.01.108
   PubMed Web of Science ®Google Scholar
• Chattopadhyay A, Wang E, Seymour R, Weaver SC, Rose JK. A chimeric vesiculo/alphavirus is an effective alphavirus vaccine. J Virol 2013; 87:395-402; PMID:23077320; http://dx.doi.org/10.1128/JVI.01860-12
   PubMed Web of Science ®Google Scholar
• Garcia-Arriaza J, Cepeda V, Hallengard D, Sorzano CO, Kummerer BM, Liljestrom P, Esteban M. A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection. J Virol 2014; 88:3527-47; PMID:24403588; http://dx.doi.org/10.1128/JVI.03418-13
   PubMed Web of Science ®Google Scholar
• Hallengard D, Lum FM, Kummerer BM, Lulla A, Lulla V, Garcia-Arriaza J, Fazakerley JK, Roques P, Le Grand R, Merits A, et al. Prime-boost immunization strategies against Chikungunya virus. J Virol 2014; 88:13333-43; PMID:25210177; http://dx.doi.org/10.1128/JVI.01926-14
   PubMed Web of Science ®Google Scholar
• Tretyakova I, Hearn J, Wang E, Weaver S, Pushko P. DNA vaccine initiates replication of live attenuated chikungunya virus in vitro and elicits protective immune response in mice. J Infect Dis 2014; 209:1882-90; PMID:24585894; http://dx.doi.org/10.1093/infdis/jiu114
   PubMed Web of Science ®Google Scholar
• Khan M, Dhanwani R, Rao PV, Parida M. Subunit vaccine formulations based on recombinant envelope proteins of Chikungunya virus elicit balanced Th1/Th2 response and virus-neutralizing antibodies in mice. Virus Res 2012; 167:236-46; PMID:22610133; http://dx.doi.org/10.1016/j.virusres.2012.05.004
   PubMed Web of Science ®Google Scholar
• Kumar M, Sudeep AB, Arankalle VA. Evaluation of recombinant E2 protein-based and whole-virus inactivated candidate vaccines against chikungunya virus. Vaccine 2012; 30:6142-9; PMID:22884660; http://dx.doi.org/10.1016/j.vaccine.2012.07.072
   PubMed Web of Science ®Google Scholar
• Tiwari M, Parida M, Santhosh SR, Khan M, Dash PK, Rao PV. Assessment of immunogenic potential of Vero adapted formalin inactivated vaccine derived from novel ECSA genotype of Chikungunya virus. Vaccine 2009; 27:2513-22; PMID:19368794; http://dx.doi.org/10.1016/j.vaccine.2009.02.062
   PubMed Web of Science ®Google Scholar
• Wagner JM, Pajerowski JD, Daniels CL, McHugh PM, Flynn JA, Balliet JW, Casimiro DR, Subramanian S. Enhanced production of Chikungunya virus-like particles using a high-pH adapted spodoptera frugiperda insect cell line. PloS one 2014; 9:e94401; PMID:24713807; http://dx.doi.org/10.1371/journal.pone.0094401
   PubMed Web of Science ®Google Scholar
• Ramsauer K, Schwameis M, Firbas C, Mullner M, Putnak RJ, Thomas SJ, Despres P, Tauber E, Jilma B, Tangy F. Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial. Lancet Infect Dis 2015; 15:519-27; PMID:25739878; http://dx.doi.org/10.1016/S1473-3099(15)70043-5
   PubMed Web of Science ®Google Scholar
• Harrison VR, Eckels KH, Bartelloni PJ, Hampton C. Production and evaluation of a formalin-killed Chikungunya vaccine. J Immunol 1971; 107:643-7
   PubMed Web of Science ®Google Scholar
• Harrison VR, Marshall JD, Guilloud NB. The presence of antibody to Chikungunya and other serologically related viruses in the sera of sub-human primate imports to the United States. J Immunol 1967; 98:979-81
   PubMed Web of Science ®Google Scholar
• Harrison VR, Binn LN, Randall R. Comparative immunogenicities of chikungunya vaccines prepared in avian and mammalian tissues. Am J Trop Med Hyg 1967; 16:786-91; PMID:4965219
   PubMed Web of Science ®Google Scholar
• McClain DJ, Pittman PR, Ramsburg HH, Nelson GO, Rossi CA, Mangiafico JA, Schmaljohn AL, Malinoski FJ. Immunologic interference from sequential administration of live attenuated alphavirus vaccines. J Infect Dis 1998; 177:634-41; PMID:9498442; http://dx.doi.org/10.1086/514240
   PubMed Web of Science ®Google Scholar
• Edelman R, Tacket CO, Wasserman SS, Bodison SA, Perry JG, Mangiafico JA. Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218. Am J Trop Med Hyg 2000; 62:681-5; PMID:11304054
   PubMed Web of Science ®Google Scholar
• Chang LJ, Dowd KA, Mendoza FH, Saunders JG, Sitar S, Plummer SH, Yamshchikov G, Sarwar UN, Hu Z, Enama ME, et al. Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial. Lancet 2014; 384:2046-52; PMID:25132507; http://dx.doi.org/10.1016/S0140-6736(14)61185-5
   PubMed Web of Science ®Google Scholar
• Tsetsarkin K, Higgs S, McGee CE, De Lamballerie X, Charrel RN, Vanlandingham DL. Infectious clones of Chikungunya virus (La Reunion isolate) for vector competence studies. Vector Borne Zoonotic Dis 2006; 6:325-37; PMID:17187566; http://dx.doi.org/10.1089/vbz.2006.6.325
   PubMed Web of Science ®Google Scholar
• Plante K, Wang E, Partidos CD, Weger J, Gorchakov R, Tsetsarkin K, Borland EM, Powers AM, Seymour R, Stinchcomb DT, et al. Novel chikungunya vaccine candidate with an IRES-based attenuation and host range alteration mechanism. PLoS Pathog 2011; 7:e1002142; PMID:21829348; http://dx.doi.org/10.1371/journal.ppat.1002142
   PubMed Web of Science ®Google Scholar
• Chu H, Das SC, Fuchs JF, Suresh M, Weaver SC, Stinchcomb DT, Partidos CD, Osorio JE. Deciphering the protective role of adaptive immunity to CHIKV/IRES a novel candidate vaccine against Chikungunya in the A129 mouse model. Vaccine 2013; 31:3353-60; PMID:23727003; http://dx.doi.org/10.1016/j.vaccine.2013.05.059
   PubMed Web of Science ®Google Scholar
• Partidos CD, Paykel J, Weger J, Borland EM, Powers AM, Seymour R, Weaver SC, Stinchcomb DT, Osorio JE. Cross-protective immunity against o'nyong-nyong virus afforded by a novel recombinant chikungunya vaccine. Vaccine 2012; 30:4638-43; PMID:22583812; http://dx.doi.org/10.1016/j.vaccine.2012.04.099
   PubMed Web of Science ®Google Scholar
• Metz SW, Martina BE, van den Doel P, Geertsema C, Osterhaus AD, Vlak JM, Pijlman GP. Chikungunya virus-like particles are more immunogenic in a lethal AG129 mouse model compared to glycoprotein E1 or E2 subunits. Vaccine 2013; 31:6092-6; PMID:24099875; http://dx.doi.org/10.1016/j.vaccine.2013.09.045
   PubMed Web of Science ®Google Scholar
• Akahata W, Yang ZY, Andersen H, Sun S, Holdaway HA, Kong WP, Lewis MG, Higgs S, Rossmann MG, Rao S, et al. A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection. Nat Med 2010; 16:334-8; PMID:20111039; http://dx.doi.org/10.1038/nm.2105
   PubMed Web of Science ®Google Scholar
• Metz SW, Gardner J, Geertsema C, Le TT, Goh L, Vlak JM, Suhrbier A, Pijlman GP. Effective chikungunya virus-like particle vaccine produced in insect cells. PLoS Negl Trop Dis 2013; 7:e2124; PMID:23516657; http://dx.doi.org/10.1371/journal.pntd.0002124
   PubMed Web of Science ®Google Scholar
• Brandler S, Lucas-Hourani M, Moris A, Frenkiel MP, Combredet C, Fevrier M, Bedouelle H, Schwartz O, Despres P, Tangy F. Pediatric measles vaccine expressing a dengue antigen induces durable serotype-specific neutralizing antibodies to dengue virus. PLoS Negl Trop Dis 2007; 1:e96; PMID:18160988; http://dx.doi.org/10.1371/journal.pntd.0000096
   PubMed Web of Science ®Google Scholar
• Brandler S, Ruffie C, Najburg V, Frenkiel MP, Bedouelle H, Despres P, Tangy F. Pediatric measles vaccine expressing a dengue tetravalent antigen elicits neutralizing antibodies against all four dengue viruses. Vaccine 2010; 28:6730-9; PMID:20688034; http://dx.doi.org/10.1016/j.vaccine.2010.07.073
   PubMed Web of Science ®Google Scholar
• Despres P, Combredet C, Frenkiel MP, Lorin C, Brahic M, Tangy F. Live measles vaccine expressing the secreted form of the West Nile virus envelope glycoprotein protects against West Nile virus encephalitis. J Infect Dis 2005; 191:207-14; PMID:15609230; http://dx.doi.org/10.1086/426824
   PubMed Web of Science ®Google Scholar
• Hilleman MR. Current overview of the pathogenesis and prophylaxis of measles with focus on practical implications. Vaccine 2001; 20:651-65; PMID:11738730; http://dx.doi.org/10.1016/S0264-410X(01)00384-X
   PubMed Web of Science ®Google Scholar
• Wong-Chew RM, Beeler JA, Audet S, Santos JI. Cellular and humoral immune responses to measles in immune adults re-immunized with measles vaccine. J Med Virol 2003; 70:276-80; PMID:12696117; http://dx.doi.org/10.1002/jmv.10390
   PubMed Web of Science ®Google Scholar
• Rager-Zisman B, Bazarsky E, Skibin A, Chamney S, Belmaker I, Shai I, Kordysh E, Griffin DE. The effect of measles-mumps-rubella (MMR) immunization on the immune responses of previously immunized primary school children. Vaccine 2003; 21:2580-8; PMID:12744894; http://dx.doi.org/10.1016/S0264-410X(03)00053-7
   PubMed Web of Science ®Google Scholar
• Seymour RL, Adams AP, Leal G, Alcorn MD, Weaver SC. A Rodent Model of Chikungunya Virus Infection in RAG1 -/- Mice, with Features of Persistence, for Vaccine Safety Evaluation. PLoS Negl Trop Dis 2015; 9:e0003800; PMID:26115459; http://dx.doi.org/10.1371/journal.pntd.0003800
   PubMed Web of Science ®Google Scholar
• Petrovsky N, Aguilar JC. Vaccine adjuvants: current state and future trends. Immunol Cell Biol 2004; 82:488-96; PMID:15479434; http://dx.doi.org/10.1111/j.0818-9641.2004.01272.x
   PubMed Web of Science ®Google Scholar
• Manzoli L, De Vito C, Salanti G, D'Addario M, Villari P, Ioannidis JP. Meta-analysis of the immunogenicity and tolerability of pandemic influenza A 2009 (H1N1) vaccines. PloS one 2011; 6:e24384; PMID:21915319; http://dx.doi.org/10.1371/journal.pone.0024384
   PubMed Web of Science ®Google Scholar
• Pellegrino P, Clementi E, Radice S. On vaccine's adjuvants and autoimmunity: Current evidence and future perspectives. Autoimmun Rev 2015; 14(10):880-8; PMID:26031899
   PubMed Web of Science ®Google Scholar
• Salazar-Gonzalez JA, Angulo C, Rosales-Mendoza S. Chikungunya virus vaccines: Current strategies and prospects for developing plant-made vaccines. Vaccine 2015; 33(31):3650-8; PMID:26073010
   PubMed Web of Science ®Google Scholar
• Yusibov V, Streatfield SJ, Kushnir N. Clinical development of plant-produced recombinant pharmaceuticals: vaccines, antibodies and beyond. Hum vaccin 2011; 7:313-21; PMID:21346417; http://dx.doi.org/10.4161/hv.7.3.14207
   PubMed Web of Science ®Google Scholar
• Pijlman GP. Enveloped virus-like particles as vaccines against pathogenic arboviruses. Biotechnol J 2015; 10:659-70; PMID:25692281; http://dx.doi.org/10.1002/biot.201400427
   PubMed Web of Science ®Google Scholar
• Metz SW, Pijlman GP. Arbovirus vaccines; opportunities for the baculovirus-insect cell expression system. J Invertebr pathol 2011; 107 Suppl:S16-30; PMID:21784227; http://dx.doi.org/10.1016/j.jip.2011.05.002
   PubMedGoogle Scholar
• Vicente T, Roldao A, Peixoto C, Carrondo MJ, Alves PM. Large-scale production and purification of VLP-based vaccines. J Invertebr pathol 2011; 107 Suppl:S42-8; PMID:21784230; http://dx.doi.org/10.1016/j.jip.2011.05.004
   PubMed Web of Science ®Google Scholar
• Barrett AD, Gould EA. Antibody-mediated early death in vivo after infection with yellow fever virus. J Gen Virol 1986; 67 (Pt 11):2539-42; PMID:3783130; http://dx.doi.org/10.1099/0022-1317-67-11-2539
   PubMed Web of Science ®Google Scholar
• Lidbury BA, Mahalingam S. Specific ablation of antiviral gene expression in macrophages by antibody-dependent enhancement of Ross River virus infection. J Virol 2000; 74:8376-81; PMID:10954537; http://dx.doi.org/10.1128/JVI.74.18.8376-8381.2000
   PubMed Web of Science ®Google Scholar
• Weaver SC, Osorio JE, Livengood JA, Chen R, Stinchcomb DT. Chikungunya virus and prospects for a vaccine. Expert Rev Vaccines 2012; 11:1087-101; PMID:23151166; http://dx.doi.org/10.1586/erv.12.84
   PubMed Web of Science ®Google Scholar
• Dowdle WR, Coleman MT, Mostow SR, Kaye HS, Schoenbaum SC. Inactivated influenza vaccines. 2. Laboratory indices of protection. Postgrad Med J 1973; 49:159-63; PMID:4803439; http://dx.doi.org/10.1136/pgmj.49.569.159
   PubMed Web of Science ®Google Scholar
• Chen RT, Markowitz LE, Albrecht P, Stewart JA, Mofenson LM, Preblud SR, Orenstein WA. Measles antibody: reevaluation of protective titers. J Infect Dis 1990; 162:1036-42; PMID:2230231; http://dx.doi.org/10.1093/infdis/162.5.1036
   PubMed Web of Science ®Google Scholar
• Ahola T, Courderc T, Ng LF, Hallengard D, Powers A, Lecuit M, Esteban M, Merits A, Roques P, Liljestrom P. Therapeutics and vaccines against chikungunya virus. Vector Borne Zoonotic Dis 2015; 15:250-7; PMID:25897811; http://dx.doi.org/10.1089/vbz.2014.1681
   PubMed Web of Science ®Google Scholar
• Fischer M, Staples JE, Arboviral Diseases Branch NCfE, Zoonotic Infectious Diseases CDC. Notes from the field: chikungunya virus spreads in the Americas - Caribbean and South America, 2013-2014. MMWR Morb Mortal Wkly Rep 2014; 63:500-1; PMID:24898168
   PubMed Web of Science ®Google Scholar
• Levitt NH, Ramsburg HH, Hasty SE, Repik PM, Cole FE, Jr., Lupton HW. Development of an attenuated strain of chikungunya virus for use in vaccine production. Vaccine 1986; 4:157-62; PMID:3020820; http://dx.doi.org/10.1016/0264-410X(86)90003-4
   PubMed Web of Science ®Google Scholar
• Piper A, Ribeiro M, Smith KM, Briggs CM, Huitt E, Nanda K, Spears CJ, Quiles M, Cullen J, Thomas ME, et al. Chikungunya virus host range E2 transmembrane deletion mutants induce protective immunity against challenge in C57BL/6J mice. J Virol 2013; 87:6748-57; PMID:23552427; http://dx.doi.org/10.1128/JVI.03357-12
   PubMed Web of Science ®Google Scholar
• Nakao E, Hotta S. Immunogenicity of purified, inactivated chikungunya virus in monkeys. Bull World Health Organ 1973; 48:559-62; PMID:4204490
   PubMed Web of Science ®Google Scholar
• Muthumani K, Lankaraman KM, Laddy DJ, Sundaram SG, Chung CW, Sako E, Wu L, Khan A, Sardesai N, Kim JJ, et al. Immunogenicity of novel consensus-based DNA vaccines against Chikungunya virus. Vaccine 2008; 26:5128-34; PMID:18471943; http://dx.doi.org/10.1016/j.vaccine.2008.03.060
   PubMed Web of Science ®Google Scholar
• Mallilankaraman K, Shedlock DJ, Bao H, Kawalekar OU, Fagone P, Ramanathan AA, Ferraro B, Stabenow J, Vijayachari P, Sundaram SG, et al. A DNA vaccine against chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates. PLoS Negl Trop Dis 2011; 5:e928; PMID:21264351; http://dx.doi.org/10.1371/journal.pntd.0000928
   PubMed Web of Science ®Google Scholar
• Bao H, Ramanathan AA, Kawalakar O, Sundaram SG, Tingey C, Bian CB, Muruganandam N, Vijayachari P, Sardesai NY, Weiner DB, et al. Nonstructural protein 2 (nsP2) of Chikungunya virus (CHIKV) enhances protective immunity mediated by a CHIKV envelope protein expressing DNA Vaccine. Viral immunology 2013; 26:75-83; PMID:23409931; http://dx.doi.org/10.1089/vim.2012.0061
   PubMed Web of Science ®Google Scholar
• Akahata W, Nabel GJ. A specific domain of the Chikungunya virus E2 protein regulates particle formation in human cells: implications for alphavirus vaccine design. J Virol 2012; 86:8879-83; PMID:22647698; http://dx.doi.org/10.1128/JVI.00370-12
   PubMed Web of Science ®Google Scholar
• Billeter MA, Naim HY, Udem SA. Reverse genetics of measles virus and resulting multivalent recombinant vaccines: applications of recombinant measles viruses. Curr Top Microbiol Immunol 2009; 329:129-62; PMID:19198565
   PubMed Web of Science ®Google Scholar
• Brandler S, Tangy F. Recombinant vector derived from live attenuated measles virus: potential for flavivirus vaccines. Comp Immunol Microbiol Infect Dis 2008; 31:271-91; PMID:17869338; http://dx.doi.org/10.1016/j.cimid.2007.07.012
   PubMed Web of Science ®Google Scholar
• Pal P, Fox JM, Hawman DW, Huang YJ, Messaoudi I, Kreklywich C, Denton M, Legasse AW, Smith PP, Johnson S, et al. Chikungunya viruses that escape monoclonal antibody therapy are clinically attenuated, stable, and not purified in mosquitoes. J Virol 2014; 88:8213-26; PMID:4135940; doi: 10.1128/JVI.01032-14
   PubMedGoogle Scholar
• Gardner CL, Hritz J, Sun C, Vanlandingham DL, Song TY, Ghedin E, Higgs S, Klimstra WB, Ryman KD. Deliberate attenuation of chikungunya virus by adaptation to heparan sulfate-dependent infectivity: a model for rational arboviral vaccine design. PLoS Negl Trop Dis 2014; 8:e2719; PMID:3930508; http://dx.doi.org/10.1371/journal.pntd.0002719
   PubMedGoogle Scholar